Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines

@article{Kim2010CharacterizationOA,
  title={Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines},
  author={Dae-Sun Kim and Jae-Hwan Nam},
  journal={Expert Opinion on Biological Therapy},
  year={2010},
  volume={10},
  pages={179 - 190}
}
Coxsackievirus strain CVB3 is widespread in the human population and causes myocarditis or pancreatitis. However, despite its clinical impact, there is no commercially available and clinically applicable prophylactic vaccine. This study examines the characteristics of attenuated CVB3 strains developed so far and their application as live-attenuated CVB3 vaccines, and discusses problems to be overcome in the development of live-attenuated vaccines. 
Application of attenuated coxsackievirus B3 as a viral vector system for vaccines and gene therapy
TLDR
This review highlights the potential use of CVB3 as a viral vector for vaccines and therapeutic gene delivery and investigates the molecular biology of these two viruses and the cellular receptors involved in their infection. Expand
Impact of genetic changes, pathogenicity and antigenicity on Enterovirus- A71 vaccine development.
TLDR
The monovalent EV-A71 IV elicits humoral immunity but lacks long-term immunogenicity and chances of reversion is reduced by presence of multiple mutations which could reduce pathogenicity. Expand
An epidemic of coxsackievirus B3 infection in infants and children in Jiangsu Province, China: a prospective cohort study
TLDR
A prospective cohort study was carried out from 2012 to 2014 in Jiangsu Province, China, and according to the results of seropositive rates and NTAb titers, an epidemic ofCVB3 infection was found, and a dynamic change in CVB3 neutralizing antibody was also observed. Expand
Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges
TLDR
This review summarizes current knowledge and strategies for developing CVBs as oncolytic viruses for cancer virotherapy and discusses the challenges arising from these studies and future prospects. Expand
EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases
TLDR
Developing multivalent EV vaccines should be strongly recommended to prevent HFMD, myocarditis, encephalitis and other severe diseases. Expand
Is a multivalent hand, foot, and mouth disease vaccine feasible?
TLDR
The current development of a bivalent inactivated EV-A71/CV-A16 vaccine is the next step toward that of multivalent HFMD vaccines, which should ultimately include other prevalent pathogenic coxsackieviruses A and CV-A10, and the prospect and challenges for the development of such multivalent vaccines are discussed. Expand
An Attenuated Coxsackievirus B3 Vector: A Potential Tool for Viral Tracking Study and Gene Delivery
TLDR
An expression vector carrying an attenuated but infectious and replicative coxsackievirus B3 genome, and unique ClaI-StuI cloning sites for an exogenous gene, whose product can be released from the nascent viral polyprotein by 2Apro cleavage is developed. Expand
The antiviral effect of jiadifenoic acids C against coxsackievirus B3
TLDR
It is shown that jiadifenoic acids C exhibit strong antiviral activities against all strains of Coxsackievirus B type 3, including the pleconaril-resistant variant. Expand
Development of a Gene Therapy Method for Cervical Cancer Using Attenuated Coxsackievirus B3 as a Vector System
TLDR
The potential use of YYFFHPV16-E7 as a gene therapy agent for treating HPV-induced cervical cancer is indicated. Expand
High proportion of coxsackievirus B3 genotype A in hand, foot and mouth disease in Zhenjiang, China, 2011-2016.
  • Xuemin Fu, Lingxiang Mao, +5 authors Chiyu Zhang
  • Biology, Medicine
  • International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 2019
TLDR
This phenomenon has revealed a new epidemic trend of CVB3 among HFMD in China, and it has epidemiological implications for monitoring the epidemic risk of Coxsackievirus B3. Expand
...
1
2
...

References

SHOWING 1-10 OF 114 REFERENCES
Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis.
TLDR
The mutant virus, YYFF, with phenylalanines substituted for two tyrosines in these conserved sequences was highly attenuated in vivo and could induce a high neutralizing antibody titer and a cytotoxic T-lymphocyte response against CVB3. Expand
Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis
TLDR
The application of an IFN-γ-expressing recombinant coxsackievirus vector is especially efficient against CVB3-induced myocarditis, which protects animals completely against subsequent lethal infections independently of the age of the immunized individual and the route of vaccine administration. Expand
Generation and analysis of an RNA vaccine that protects against coxsackievirus B3 challenge.
TLDR
Despite failing to induce detectable neutralizing antibodies, the candidate RNA vaccine conferred substantial protection against virus challenge, either with an attenuated recombinant CVB3, or with the highly pathogenic wt virus. Expand
Protection of Mice against Lethal Coxsackievirus B3 Infection by Using DNA Immunization
TLDR
ABSTRACT Vaccination with DNA and recombinant vaccinia viruses (rec.VV) has been studied with the coxsackievirus B3 (CVB3) model system and DNA vaccination with the major structural protein VP1 protected 72.2% of mice from lethal challenge, whereas VP1 expressed by rec.V V was much less efficient. Expand
High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis.
TLDR
It is shown that vaccine can be made against Coxsackie B3 virus with good protective effect and significant neutralisation antibody titre and the emergence of chronic enteroviral diseases as a concept prompted attempts to produce anEnteroviral vaccine. Expand
Enhancement of coxsackievirus B3 infection by antibody to a different coxsackievirus strain.
TLDR
Results have implications for human disease as infection with multiple strains likely occurs during the lifetime of an individual and raises the possibility of antibody enhancement of infectivity (AEI) by cross-reactive but non-neutralizing antibody to a different strain from a prior infection. Expand
Vaccination procedures against Coxsackievirus-induced heart disease
TLDR
Using different murine model systems it has been demonstrated that classic as well as newly developed vaccination procedures are quite successful in preventing Coxsackievirus B3 infections. Expand
Coxsackie B viruses and the kidney--a neglected topic.
  • A. Pasch, F. Frey
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2006
TLDR
An overview of Coxsackie B viruses types 1-6 is provided, and of the slowly and steadily increasing evidence suggesting a link between coxsackieviral infections and kidney diseases is provided. Expand
Vaccination of Balb/c mice against enteroviral mediated myocarditis.
TLDR
It is suggested that vaccination might be a possible way of prophylaxis for myocarditis and even dilated cardiomyopathy, the latter presently being the chief cause of heart transplantation. Expand
Direct interferon-γ-mediated protection caused by a recombinant coxsackievirus B3
TLDR
In vitro, cocultivation of CVB3(IFN-γ)-infected cells induced a reduction ofCVB3H3 replication and virus-induced cytopathogenicity, and local expression of specific cytokines by recombinant CVB 3 confers prevention of virus-caused myocarditis. Expand
...
1
2
3
4
5
...